
			Former chemistry professor, Desh Bandhu Gupta, dipped into his wife's savings to buy a tiny vitamin company in 1968. Today his Lupin is India's second largest generics firm deriving more than half of its $2.1 billion revenues from the U. S. and Japan. Run by daughter Vinita and son Nilesh, it has been on an acquisition spree to expand its global footprint, notably in Japan. Lupin's most recent acquisition in that country, a portfolio of 21 brands from Osaka-based Shionogi, has boosted its position to the sixth largest generics player in the Japanese market.
		